Adjusted Net Income Six Months Ended Six Months Ended
June 30, 2008 June 30, 2007
Net Income (Loss) Diluted EPS Net Income Diluted Diluted
EPS Net Income EPS
Adjusted Amount - Non GAAP $5,565,142 $0.26 $5,342,343 $0.25
Non-cash employee compensation (1) $1,263,188 $0.06 -- --
Amount per consolidated statement $4,301,954 $0.20 $5,342,343 $0.25
(1) Non-cash compensation expense of $1,263,188 in connection with
adoption of the equity incentive plan granting share options on the
Company's common stock to employees and directors
Use of Non-GAAP Financial Measures
GAAP results for the three months ended June 30, 2008 include non-cash stock based compensation charges. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item in this release. The Company's management believes that this non-GAAP measure provides investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned
subsidiary Shandong Taibang, is currently the only plasma-based
biopharmaceutical company approved by the government of Shandong Province,
the second largest province with a population
|SOURCE China Biologic Products, Inc.|
Copyright©2008 PR Newswire.
All rights reserved